Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

By Ludwig Burger FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want ...

FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing the macro-economic and geopolitical environment as well ...

Merck KGaA, the German science and technology group, trimmed its profit forecast, citing a weakening US dollar and ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in ...